{"id":"https://openalex.org/W7223189252","doi":"https://doi.org/10.3389/fphar.2026.1944368","title":"Potential association between IL-12/23, IL-23, and IL-17 inhibitors and skin cancer: a pharmacovigilance study based on the FAERS database","display_name":"Potential association between IL-12/23, IL-23, and IL-17 inhibitors and skin cancer: a pharmacovigilance study based on the FAERS database","publication_year":2026,"publication_date":"2026-10-22","ids":{"openalex":"https://openalex.org/W7223189252","doi":"https://doi.org/10.3389/fphar.2026.1944368","pmid":"https://pubmed.ncbi.nlm.nih.gov/42991782","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13736627"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1944368","doi":"https://doi.org/10.3389/fphar.2026.1944368","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1944368","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1944368/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1944368/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053330684","display_name":"Xing Jiang","orcid":"https://orcid.org/0000-0002-3096-2716","observed_orcids":["https://orcid.org/0000-0002-3096-2716"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xing Jiang","raw_affiliation_strings":["Department of Pharmacy, People\u2019s Hospital of Mianzhu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, People\u2019s Hospital of Mianzhu","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159235153","display_name":"Yunbei Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yunbei Huang","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","School of Pharmacy, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]},{"raw_affiliation_string":"School of Pharmacy, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159240674","display_name":"Min Xie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Min Xie","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","School of Pharmacy, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]},{"raw_affiliation_string":"School of Pharmacy, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101907890","display_name":"Peng Li","orcid":"https://orcid.org/0000-0003-3741-6387","observed_orcids":["https://orcid.org/0000-0003-3741-6387"]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Li Peng","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","School of Pharmacy, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]},{"raw_affiliation_string":"School of Pharmacy, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064402330","display_name":"Mengyao Xu","orcid":"https://orcid.org/0009-0008-3295-661X","observed_orcids":["https://orcid.org/0009-0008-3295-661X"]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Mengyao Xu","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033553057","display_name":"Zhongyu Qi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhongyu Qi","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159250765","display_name":"Guojun Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Guojun Wang","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5034770263","display_name":"Xiaofeng Pu","orcid":"https://orcid.org/0009-0000-0450-1169","observed_orcids":["https://orcid.org/0009-0000-0450-1169"]},"institutions":[{"id":"https://openalex.org/I3017480383","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I3017480383"]},{"id":"https://openalex.org/I4210086248","display_name":"Affiliated Hospital of Southwest Medical University","ror":"https://ror.org/0014a0n68","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210086248"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xiaofeng Pu","raw_affiliation_strings":["Department of Pharmacy, The Affiliated Hospital, Southwest Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5034770263"],"corresponding_institution_ids":["https://openalex.org/I3017480383","https://openalex.org/I4210086248"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.80039769,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":"1944368","last_page":"1944368"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9595000147819519,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9595000147819519,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.01769999973475933,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/il-12-23-inhibitors","display_name":"IL-12/23 inhibitors","score":0.9359999895095825},{"id":"https://openalex.org/keywords/il-23-inhibitors","display_name":"IL-23 inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/il-17-inhibitors","display_name":"IL-17 inhibitors","score":1.0},{"id":"https://openalex.org/keywords/skin-cancer","display_name":"skin cancer","score":0.9739999771118164},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.4909999966621399},{"id":"https://openalex.org/keywords/risankizumab","display_name":"risankizumab","score":0.878000020980835},{"id":"https://openalex.org/keywords/tildrakizumab","display_name":"tildrakizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/ustekinumab","display_name":"ustekinumab","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5350000262260437},{"id":"https://openalex.org/keywords/psoriasis","display_name":"psoriasis","score":0.6430000066757202},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.5830000042915344},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.6510000228881836},{"id":"https://openalex.org/keywords/concomitant-medications","display_name":"concomitant medications","score":0.4959999918937683}],"concepts":[{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.9326000213623047},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8952999711036682},{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.8766000270843506},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.6633999943733215},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.550000011920929},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.521399974822998},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5209000110626221},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4235999882221222},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.3610999882221222},{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.34220001101493835},{"id":"https://openalex.org/C23276603","wikidata":"https://www.wikidata.org/wiki/Q158230","display_name":"Pharmacoepidemiology","level":3,"score":0.33379998803138733},{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.32739999890327454},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.322299987077713},{"id":"https://openalex.org/C142853389","wikidata":"https://www.wikidata.org/wiki/Q744778","display_name":"Association (psychology)","level":2,"score":0.3203999996185303},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.30480000376701355},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.30320000648498535},{"id":"https://openalex.org/C2780542314","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Adverse drug reaction","level":3,"score":0.2978000044822693},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.28769999742507935},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.2858000099658966},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2802000045776367},{"id":"https://openalex.org/C187960798","wikidata":"https://www.wikidata.org/wiki/Q7631152","display_name":"Subgroup analysis","level":3,"score":0.26930001378059387},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.2605000138282776},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.25870001316070557},{"id":"https://openalex.org/C11988809","wikidata":"https://www.wikidata.org/wiki/Q412889","display_name":"Interleukin 6","level":3,"score":0.2547000050544739},{"id":"https://openalex.org/C146304588","wikidata":"https://www.wikidata.org/wiki/Q961652","display_name":"Case-control study","level":2,"score":0.25459998846054077}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fphar.2026.1944368","doi":"https://doi.org/10.3389/fphar.2026.1944368","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1944368","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1944368/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmid:42991782","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42991782","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13736627","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13736627/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Pharmacol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:362e2c9608d04510b8f5d8179abe42aa","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/362e2c9608d04510b8f5d8179abe42aa","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1944368","doi":"https://doi.org/10.3389/fphar.2026.1944368","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1944368","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1944368/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[{"id":"https://openalex.org/G3577408329","display_name":null,"funder_award_id":"2024ZKY049","funder_id":"https://openalex.org/F4320328652","funder_display_name":"Southwest Medical University"}],"funders":[{"id":"https://openalex.org/F4320328652","display_name":"Southwest Medical University","ror":"https://ror.org/00g2rqs52"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223189252.pdf","grobid_xml":"https://content.openalex.org/works/W7223189252.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W1488772574","https://openalex.org/W1892676932","https://openalex.org/W1984467626","https://openalex.org/W2006290765","https://openalex.org/W2052313621","https://openalex.org/W2064470823","https://openalex.org/W2091378964","https://openalex.org/W2390922210","https://openalex.org/W2583474867","https://openalex.org/W2589472507","https://openalex.org/W2777952438","https://openalex.org/W2889338440","https://openalex.org/W3028017255","https://openalex.org/W3109326355","https://openalex.org/W3180882235","https://openalex.org/W3194398820","https://openalex.org/W3216657315","https://openalex.org/W4200071760","https://openalex.org/W4231768387","https://openalex.org/W4248366890","https://openalex.org/W4291743201","https://openalex.org/W4292794405","https://openalex.org/W4310481530","https://openalex.org/W4310553624","https://openalex.org/W4367043311","https://openalex.org/W4376631082","https://openalex.org/W4381715253","https://openalex.org/W4386613592","https://openalex.org/W4389149791","https://openalex.org/W4390050935","https://openalex.org/W4393935425","https://openalex.org/W4396696202","https://openalex.org/W4401978395","https://openalex.org/W4404587356","https://openalex.org/W4410520741","https://openalex.org/W4410551585","https://openalex.org/W7118074907","https://openalex.org/W7167976043"],"related_works":["https://openalex.org/W7222954494","https://openalex.org/W4400271844","https://openalex.org/W4386116624","https://openalex.org/W4378808136","https://openalex.org/W4365458036","https://openalex.org/W4386879384","https://openalex.org/W3094415075","https://openalex.org/W4229055052","https://openalex.org/W4406611038","https://openalex.org/W7196932830"],"abstract_inverted_index":{"Background":[0],"Interleukin":[1],"(IL)-12/23,":[2],"IL-23,":[3,71],"and":[4,59,72,75,82,88,139,155,187,219,224,242],"IL-17":[5,73,150,230],"inhibitors":[6,74,151],"are":[7],"increasingly":[8],"used":[9],"for":[10,110,118,173,185,229,246],"immune-mediated":[11],"inflammatory":[12],"diseases,":[13],"yet":[14],"their":[15],"long-term":[16],"risk":[17],"of":[18,98,212],"skin":[19,76,100,213],"cancer":[20,101,214],"remains":[21],"unclear":[22],"due":[23],"to":[24,52,65,256],"limited":[25],"evidence":[26],"from":[27,42,50,237],"randomized":[28],"controlled":[29],"trials.":[30],"Methods":[31],"We":[32],"conducted":[33],"a":[34,181,238],"disproportionality":[35,106],"analysis":[36,91,179],"using":[37],"individual":[38],"case":[39],"safety":[40],"reports":[41,102,216],"the":[43,67,115,244],"FDA":[44],"Adverse":[45],"Event":[46],"Reporting":[47,55],"System":[48],"(FAERS)":[49],"2004":[51],"2025":[53],"Q2.":[54],"odds":[56],"ratios":[57],"(ROR)":[58],"information":[60],"components":[61],"(IC)":[62],"were":[63,92,103,108,156],"calculated":[64],"assess":[66],"association":[68,165],"between":[69],"IL-12/23,":[70],"cancer.":[77],"Subgroup":[78],"analyses":[79,197],"by":[80],"age":[81],"sex,":[83],"time-to-onset":[84],"analysis,":[85],"Weibull":[86,178],"modeling,":[87],"co-medication":[89],"interaction":[90],"further":[93,253],"performed.":[94],"Results":[95],"A":[96],"total":[97],"3,661":[99],"identified.":[104],"Significant":[105],"signals":[107,154,228],"observed":[109],"most":[111],"interleukin":[112],"inhibitors,":[113,221],"with":[114,226],"strongest":[116],"associations":[117],"risankizumab":[119,223],"(ROR":[120,130,141],"8.01,":[121],"95%":[122,132,143],"CI":[123,133,144],"7.62\u20138.42;":[124],"IC":[125,135,146],"025":[126,136,147],",":[127,137,148],"2.88),":[128],"tildrakizumab":[129],"5.81,":[131],"4.13\u20138.19;":[134],"1.84),":[138],"ustekinumab":[140,186],"5.53,":[142],"5.23\u20135.85,":[145],"2.35).":[149],"showed":[152],"weaker":[153,227],"no":[157],"longer":[158],"significant":[159,201],"in":[160,169,215,249],"psoriasis-restricted":[161],"sensitivity":[162],"analyses.":[163],"The":[164],"was":[166],"more":[167],"pronounced":[168],"elderly":[170],"patients,":[171,251],"especially":[172],"those":[174],"aged":[175],">75":[176],"years.":[177],"indicated":[180],"wear-out":[182],"failure":[183],"pattern":[184],"risankizumab,":[188],"suggesting":[189],"an":[190],"increasing":[191],"reporting":[192,203,211,240],"frequency":[193],"over":[194],"time.":[195],"Co-medication":[196],"did":[198],"not":[199],"reveal":[200],"synergistic":[202],"signals.":[204],"Conclusion":[205],"This":[206],"pharmacovigilance":[207],"study":[208],"identified":[209],"disproportionate":[210],"involving":[217],"IL-12/23":[218],"IL-23":[220],"particularly":[222],"ustekinumab,":[225],"inhibitors.":[231],"These":[232],"findings":[233],"represent":[234],"signal":[235],"detection":[236],"spontaneous":[239],"database":[241],"highlight":[243],"need":[245],"dermatological":[247],"monitoring":[248],"high-risk":[250],"warranting":[252],"prospective":[254],"investigation":[255],"clarify":[257],"clinical":[258],"significance.":[259]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-22T00:00:00"}